tradingkey.logo

Journey Medical Corp

DERM
8.950USD
-0.240-2.61%
Horário de mercado ETCotações atrasadas em 15 min
210.07MValor de mercado
PerdaP/L TTM

Journey Medical Corp

8.950
-0.240-2.61%

Mais detalhes de Journey Medical Corp Empresa

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.

Informações de Journey Medical Corp

Código da empresaDERM
Nome da EmpresaJourney Medical Corp
Data de listagemNov 12, 2021
CEOMr. Claude Maraoui
Número de funcionários41
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 12
Endereço9237 E Via De Ventura Blvd., Suite 105
CidadeSCOTTSDALE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal85258
Telefone14804346670
Sitehttps://journeymedicalcorp.com/
Código da empresaDERM
Data de listagemNov 12, 2021
CEOMr. Claude Maraoui

Executivos da empresa Journey Medical Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+53.80%
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+150.79%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+15.25%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+17.37%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+40.22%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+25.35%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+25.35%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%
Por RegiãoUSD
Nome
Receita
Proporção
United States
15.01M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Qbrexa
6.95M
46.30%
Accutane
3.40M
22.62%
Emrosi
2.79M
18.62%
Amzeeq
879.00K
5.86%
Other branded revenue
735.00K
4.90%
Zilxi
256.00K
1.71%

Distribuição de ações

Atualizado em: ter, 14 de out
Atualizado em: ter, 14 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
Outro
55.72%
Investidores
Investidores
Proporção
Fortress Biotech Inc
16.55%
Maraoui (Claude)
10.15%
Tang Capital Management, LLC
9.13%
Wasatch Global Investors Inc
5.67%
The Vanguard Group, Inc.
2.78%
Outro
55.72%
Tipos de investidores
Investidores
Proporção
Corporation
16.55%
Individual Investor
16.12%
Hedge Fund
10.86%
Investment Advisor
10.71%
Investment Advisor/Hedge Fund
10.28%
Insurance Company
0.89%
Research Firm
0.32%
Private Equity
0.16%
Pension Fund
0.07%
Outro
34.04%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
113
6.77M
33.31%
+424.31K
2025Q2
93
10.34M
59.77%
+53.87K
2025Q1
89
9.75M
61.79%
-68.70K
2024Q4
83
8.33M
55.97%
-821.12K
2024Q3
84
6.72M
45.26%
-1.40M
2024Q2
79
7.11M
49.43%
-621.27K
2024Q1
70
6.34M
49.52%
-781.26K
2023Q4
68
5.80M
46.63%
-1.25M
2023Q3
54
6.63M
53.88%
+189.20K
2023Q2
50
5.90M
48.59%
-532.43K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fortress Biotech Inc
3.36M
16.55%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
10.15%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
9.13%
--
--
Jun 30, 2025
Wasatch Global Investors Inc
1.15M
5.67%
+221.46K
+23.80%
Jun 30, 2025
The Vanguard Group, Inc.
564.99K
2.78%
+192.73K
+51.77%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
480.30K
2.36%
+437.14K
+1012.83%
Jun 30, 2025
Rosenwald (Lindsay A)
377.89K
1.86%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
228.20K
1.12%
+216.74K
+1890.08%
Jun 30, 2025
Alloush (Ramsey)
316.68K
1.56%
+46.86K
+17.37%
Jun 17, 2025
Geode Capital Management, L.L.C.
262.35K
1.29%
+148.61K
+130.66%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Royce Quant Small-Cap Quality Value ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI